#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Transient ischaemic attack Ureteric cancer Retinitis pigmentosa Toxic epidermal necrolysis Glomerulonephritis chronic Infertility male Head and neck cancer Malignant central nervous system neoplasm Fibrous dysplasia of bone Palmar-plantar erythrodysaesthesia syndrome Cutaneous calcification Undifferentiated sarcoma Advanced systemic mastocytosis Familial haemophagocytic lymphohistiocytosis Anti-glomerular basement membrane disease More trials…

    Learn about Rare Diseases

    Medulloblastoma – Basic Information Friedreich’s ataxia – Treatment Acquired haemophilia Idiopathic pulmonary fibrosis – Life with Disease Propionic acidaemia – Treatment Ewing’s sarcoma recurrent – Trials in Disease Haemophilia A without inhibitors Short-bowel syndrome – Treatment Marginal zone lymphoma – Trials in Disease Hereditary ataxia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ds-2325A S227928 Imidapril Hydrochloride Futibatinib FRUQUINTINIB Agomelatine Rilzabrutinib Alendronate Sodium Monohydrate TRIGLYCERIDES MEDIUM CHAIN Diphenhydramine Relacorilant Rintatolimod Regn9933 Bupivacaine Tazobactam Sodium Itraconazole Afm24 Nadroparin Calcium ETX-19477 Fosaprepitant More therapies…

    Learn about Your Condition

    Asymptomatic HIV infection Stomatitis Chronic disease Burkitt's lymphoma Anaemia of chronic disease Diabetes mellitus Ear discomfort Staphylococcal bacteraemia Hydrocele Rectal adenocarcinoma Metastatic malignant melanoma Ichthyosis Laryngeal cancer stage I Respiratory distress Myxofibrosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga…

Niepubliczny Zakład Opieki Zdrowotnej Vivamed Jadwiga Miecz

Ul. Zamiejska 17, Warsaw, 03-580, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Guselkumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    Croatia Czechia France Germany Hungary Italy +4
  • Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Gs-1427
    Austria Belgium Czechia France Germany Hungary +4
  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    • Ustekinumab
    Belgium Croatia Czechia France Germany Hungary +7
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia France +13
  • Study on Long-Term Effects of Mirikizumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Mirikizumab
    Austria Belgium Czechia Denmark France Hungary +8
  • Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Croatia Czechia Estonia Finland +14
  • Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Vedolizumab
    Bulgaria Czechia Hungary Latvia Poland Romania +1
  • Study on Tulisokibart for Treating Moderate to Severe Crohn’s Disease in Adults

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Azd7798
    Austria Belgium Bulgaria Croatia France Germany +8
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!